RBC Capital downgraded uniQure N.V. (QURE) from Outperform to Sector Perform on March 02, 2026. The move is the primary QURE analyst rating update today and it came with a new price target of $11. We track a second firm, Cantor Fitzgerald, which downgraded QURE the same morning. Together these changes mark a clear shift in analyst sentiment after a recent FDA recommendation and are central to near-term trading and risk assessment for investors.

QURE analyst rating: RBC Capital downgrade on March 02, 2026

RBC Capital changed its rating at 11:33 AM on March 02, 2026, moving uniQure N.V. (QURE) from Outperform to Sector Perform. RBC also lowered its price target to $11, signaling reduced visibility on upside after regulatory developments. The analyst note cited an FDA-linked setback and cut assumptions on near-term approvals and adoption. See the official street report for details: RBC Capital Downgrades uniQure BV (QURE) to Sector Perform, Lowers PT to $11.

Cantor Fitzgerald downgrades and timing in the QURE analyst rating mix

Cantor Fitzgerald downgraded uniQure at 10:14 AM on March 02, 2026, moving from Overweight to Neutral after an FDA recommendation. The firm flagged higher regulatory risk, which trimmed its conviction on outperformance. Cantor’s action preceded RBC’s note and pushed short-term sentiment weaker. Full Cantor coverage is available here: Cantor Fitzgerald Downgrades uniQure BV (QURE) to Neutral following FDA recommendation.

What the rating changes mean for investors and risk

A shift from Outperform/Overweight to Sector Perform/Neutral lowers analyst conviction on upside. Investors should treat these QURE analyst rating moves as a signal to reweight regulatory and trial risk in position sizing. The new RBC $11 target defines a nearer-term upside ceiling based on RBC’s assumptions. Cantor’s neutral view implies investors may expect more sideways trading until clearer regulatory outcomes.

Stock reaction and short-term market impact

Market quotes show immediate moves after the notes: the RBC-related move tracked a 5.63% price change of $0.56, and the Cantor note tracked a 4.53% move of $0.46. uniQure’s market cap is $646,839,900, which keeps the company in a small-cap trading cohort. These rating changes increased volatility and trading volume as investors re-priced regulatory risk.

Historical analyst coverage and regulatory context for QURE

Analyst coverage of uniQure has oscillated with clinical and regulatory news over the last three years. Major firms previously held bullish views on gene therapy commercialization, but recent FDA guidance reduced certainty. The March 02, 2026 downgrades follow that pattern where regulatory signals trigger multiple downgrades in quick succession.

Meyka AI view and the proprietary grade for QURE

Meyka AI rates QURE with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. We note the grade is not a recommendation. Meyka’s real-time feed shows analyst sentiment shifting lower after March 02, 2026, and we flag elevated regulatory risk in our models. For the company profile and live metrics see the QURE profile on Meyka.

Final Thoughts

The March 02, 2026 analyst actions by RBC Capital and Cantor Fitzgerald mark a clear re-rating of uniQure N.V. Investors should view the QURE analyst rating changes as a reallocation of risk from an upside bias to a more cautious stance. RBC’s downgrade to Sector Perform and its $11 price target set a nearer-term reference point for upside. Cantor’s move from Overweight to Neutral signals that at least two major houses prefer to wait for regulatory clarity before adding exposure.

For investors this means tighter stop-loss discipline, smaller position sizes, or using options to manage event risk are reasonable tactics. The $646,839,900 market cap keeps uniQure in a category where single regulatory events can swing consensus quickly. Meyka AI’s model rates QURE B+, reflecting mixed fundamentals with higher regulatory uncertainty now priced in. Use this information with your own research; we are not financial advisors but an AI-powered market analysis platform tracking QURE analyst rating developments in real time.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.